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B164 - EBV REACTIVATION ASSOCIATED POST-TRANSPLANT 
LYMPHOPROLIFERATIVE DISEASE, CLONAL GAMMOPATHY AND OUTCOMES IN 
ALLOGENEIC T-CELL DEPLETED STEM CELL TRANSPLANTS FOR MYELOID 
MALIGNANCIES  
Varun Mehra1, Eleanor Barnwell1, Ute Boczek1, Stefani Widya2, Adrian Choy2, 
Alessandra Bisquera3, Kavita Raj1,4, Donal Mclornan1,4, Shreyans Gandhi1, Austin 
Kulasekararaj1, Hugues de Lavallade1, Victoria Potter1, Ghulam Mufti1,2, Antonio 
Pagliuca1 1Kings College Hospital, Haematology, London, United Kingdom, 2GKT 
School of Medicine, London, Haematology, London, United Kingdom, 3King's College 
London, Division of Health and Social Care Research, London, United Kingdom, 
4Guy's and St Thomas' Hospital, Haematology, London, United Kingdom  
Background: Ebstein Barr Virus is frequently reactivated(EBV-R) in 
immunocompromised allogeneic haematopoietic stem cell transplant(HSCT) patients 
following T cell depletion(TCD). Incidental observations of monoclonal 
gammopathy(MG or M-protein) post-HSCT have also been reported. We report on 
incidence & outcomes of EBV-R,PTLD and association with M-protein in a large 
cohort of in-vivo TCD allogeneic HSCTs and provide quantitative underpinning to 
decisions about pre-emptive treatment for post-transplant lymphoproliferative 
disease (PTLD). 
Methods: This is a single-centre retrospective analysis of 293 consecutive patients 
who underwent TCD allo-HSCTs for myeloid malignancies between January 2012-
June 2016. EBV-DNA was monitored frequently on whole blood samples with 
standardised quantitative real-time PCR. Serum protein electrophoresis was routinely 
tested with immunoglobulin subclasses identified by immunofixation electrophoresis. 
Histological confirmation of PTLD was based on standard WHO diagnostic criteria 
('proven'), while those without biopsy were classed as 'probable' based on clinical & 
radiological criteria as defined by ECIL-6 guidelines. 
Results: Majority of patients had AML(n-152/293) and MDS(n-107/293) with a 
median age of 58 years(range 22-76). Median follow up of survivors was 32 
months(range 4-65). Majority of patients(n-220/293;75%) developed EBV-R with a 
median time of 79 days[Inter quartile range(IQR) 27-160 days] &higher cumulative 
incidence with ATG(n-132) versus Alemtuzumab(n-161)(p< 0.001). Figure-1a shows 
schematic representation of EBV and PTLD events (cumulative incidence of 
6.8%(95%CI-4.0%-10.6%) at 12 months). Significantly higher peak EBV DNA viral 
load(EVL) were noted in patients with PTLD(p-< 0.001).Development of post-HSCT 
MG was observed in 29%(n-85/292). ROC curve identified peak blood EVL>150,000 
copies/ml significantly correlated with risk of developing PTLD (sensitivity-
70.6%,specificity-79.4%;AUC-0.82,p< 0.001). Based on these estimates, subgroup of 
patients with no EBV-R(n-72/292), peak EVL < 150,000(< 150k)copies/ml(n-165/292) 
& >150,000(>150k)copies/ml(n-55/292) were categorised in 6 groups along patients 
with/without MG accordingly (Groups 1-6;Figure-1b). Patients with EBV-R had 
significantly better OS [5-year OS of 52% vs 35%(no EBV-R);Log-rank p< 0.001],with 
this survival benefit mainly driven by subgroup of patients with lower EVL(< 150k)(p< 
0.001). PTLD patients had trend towards inferior 3-year OS(15% vs 54%;p-0.051). 
Patients with MG had a significantly better OS irrespective of degree of EVL(Group 1-
3,p< 0.001).We report a 'sweet spot' of low EVL & presence of MG in these patients, 
with a clear survival advantage compared to those with no EBV-R and/or no M-
protein (Group-2 5-year OS 62% vs 27% in Group-6; HR-0.15;95%CI:0.06-0.34;p< 
0.001;Figure1b). Overall cumulative incidence of relapse (CIR) was 28%(95%CI:23-37) 
and non-relapse-mortality(NRM) of 24%(95%CI:18.6-30) at 5 years. Multivariate 
analysis(MVA) revealed absence of M-protein,high EVL (>150k copies/ml) or no EBV-
R and absence of any GVHD as significant factors for high CIR. Similarly, high EVL or 
no EBV-R, absence of M-protein and ITU admission were significant predictors of 
high NRM. 
Conclusions: This study adds to our understanding of role of EBV viraemia & 
associated MG in TCD-HSCTs while highlighting its significant impact on risk of PTLD, 
OS, NRM & CIR. Low EBV burden and development of MG is protective with 
significantly better survival outcomes and we recommend pre-emptive approach of 
using Rituximab for EBV-R /PTLD is best employed at higher EBV burden (e.g. >150k 
copies/ml DNA) in high risk patients and be prospectively evaluated in future studies. 
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